Pulmonary hypertension can occur either as primary or secondary disease following cardiac or pulmonary illnesses. In either cases, histological lung biopsies reveal vascular remodelling i.e. smooth muscle cells proliferation with medial hypertrophy, arteriolar muscularization and endothelial cell proliferation. Subsequent intimal thickening, fibrosis and in situ thrombosis, altogether lead to vaso-occlusive alterations referred to as plexiform lesions.
Definition-causes
cases of initial pulmonary diseases, pulmonary hypertension can be directly related to hypoxia such as in chronic Pulmonary hypertension is defined by a mean pulmonpulmonary obstructive disease and sleep apnea syndrome, ary arterial pressure exceeding 25 mm Hg at rest or 30 mm or to a mechanical obstruction to vascular flow for Hg during exercise [1] . Contrasting the normally lowexample in post-thrombotic diseases [3] . The recognised pressured pulmonary vascular circuit, it is due to increased causes of secondary pulmonary hypertension are listed in pulmonary vascular resistance's. It occurs either as a the Table 1 . There are also some clinical conditions primary or secondary disease following pulmonary or associated with an increased incidence of pulmonary cardiac illnesses. The initial cardiac diseases include both hypertension i.e. diffuse connective tissue diseases, HIV high pressure diseases (i.e. left ventricular failure) and high infection, anorectic drugs and portal hypertension secblood flow diseases (i.e. congenital heart defects) [2] . In ondary to liver cirrhosis [4] ( Table 1 ). The precapillary pulmonary hypertension often noted in these conditions is considered as a primary form of pulmonary hypertension In chronic pulmonary hypertension, although the entire may suggest an inherent predisposition to pulmonary pulmonary vascular tree undergoes histological alterations, hypertension, with HIV infection or anorectic drugs acting it is the smaller vessels (arterioles and venules) which are as mere triggering factors [4] . Familial cases of pulmonary primarily affected. These alterations include smooth mushypertension have been described via an autosomal domicle cells proliferation with medial hypertrophy and arterionant transmission mode with incomplete penetrance. The lar muscularization, fibrosis, in situ thrombosis and endogene has been localised on chromosome 2 [9] . thelial cells proliferation with subsequent intimal thickening [11] [12] [13] . In cases of primary pulmonary hypertension, endothelial cells proliferation is monoclonal [14, 15] .
The primary stimuli of pulmonary hypertension
Concentric endothelial cell proliferation and smooth muscle cell migration leads to so called plexiform lesions The most frequent initial stimuli of pulmonary hypertenwhich seem to be unique to the pulmonary circulation. sion are hypoxia and mechanical obstruction to pulmonary These plexiform lesions were initially exclusively associarterial flow. Acute hypoxia increases pulmonary arterial ated with primary pulmonary hypertension but are in fact a pressure almost instantly, but the phenomenon is reversible feature of both primary and secondary pulmonary hywith the recovery of a normal oxygen concentration.
pertension. Sustained hypoxia leads to durable elevated pulmonary arterial pressure, with partly irreversible vasoconstriction, 3.1. Smooth muscle cell proliferation which is only partially improved by oxygen supplementation [10] . During sustained hypoxia, pulmonary Sustained pulmonary hypertension leads to enhanced arterial pressure also rises as a result of progressive small muscularization of small arterioles, whose wall usually vessels' obliterative changes. The reasons why chronic consists of a single elastic layer. This process is found hypoxia leads to these effects are not clearly understood even in very distal arteries (15 mm in diameter). The newly [10] except in cases of pulmonary hypertension secondary formed muscular layer is situated between the former to thromboembolism: in cases of large pulmonary (main, elastic (outer) layer and a de novo elastic (inner) layer lobar or segmental) vessels' chronic obliteration, the initial which is bordered by intimal cells [13, 16] . Since this arterial emboli which are not completely dissolved by local muscularization also occurs in pulmonary venules and in fibrinolysis, become endothelialized and the vessel recanaladults born at high altitude, who are free of cardiac and ized. These new vessels lack the main physiological pulmonary diseases, alveolar hypoxia is suspected to be In some cases of pulmonary hypertension, using impressure level [1] . In these modified, exceedingly musmunoperoxydase staining with antibodies to factor-VIIIcularized arterioles, smooth muscle cells undergo morrelated antigen, plexiform lesions were related to a process phological and functional changes [13] . Whereas normally of endothelial cells proliferation [30] . The authors sugthey are purely contractile, these arterial smooth muscle gested that endothelial proliferation contributes to the final cells mature and acquire abnormal proliferative, migratory obliteration of small vessels. However, the reason for this and synthetic properties. The conversion of smooth muscle stimulation and its mediators remain to be elucidated. cells from a contractile to a migratory phenotype seems to Recently, Lee et al. showed that the endothelial proliferdepend upon growth factors (transforming growth factor b ation is monoclonal in primary pulmonary hypertension and basic fibroblast growth factor) [18] released by the suggesting that a somatic genetic alteration process could action of vascular elastase on elastin and proteoglycans be involved in its pathogenesis [14, 15] . which stores these growth factors [19] . Elastin peptides also stimulate the change from contractile to migratory phenotype [19] . Consecutively, the smooth muscle cells 4. The role of factors produced by endothelial cells migrate through the outer elastic layer into the intima and platelets in the pathogenesis of sustained where they proliferate and may invade the vascular lumen vasoconstriction and vascular remodeling ( Fig. 1 ) altogether forming concentric layers referred to as 'onionskin lesions'. The final stage with vessel occlusion is As soon as arterial layers' remodeling occurs with called plexiform lesions.
increased wall thickness and decreased arterial diameter, the pulmonary vessels become less responsive to further vasodilatation stimuli. Concomitant increase in vascular 3.2. Fibrosis wall shear stress leads to further endothelial functional impairment. While endothelial histological changes can be An increase of extracellular matrix turn-over and numconsidered as secondary to a causal disease in secondary ber of vascular fibroblasts, which produce components like pulmonary hypertension, in primary pulmonary hypertenelastin and collagen, is demonstrated. The enhanced matrix sion there is still a debate whether the endothelial dysfuncsynthesis versus its destruction leads to vascular stiffness tion is the cause or merely a marker of the disease [31] . [20] . Peacock et al. hypothesised that this intensified
The endothelium normally releases both vasoconstrictor matrix synthesis could be an adaptive response of the and growth-promoting factors like endothelin, or vasodilatarterial vessels in order to maintain prolonged vasoconor and growth-inhibitor factors such as prostacyclin and striction during sustained hypoxia, without increased NO [21], responsible of local vascular homeostasis. Endoenergy expenditure [21] . The matrix destruction depends thelial dysfunction or lesions lead to impaired production on elastolysis. Enhanced elastolysis occurs early in the and / or release of these factors. pathological process, before vascular remodelling is detected [22] , and is secondary to local vascular elastase 4.1. Role of endothelin-1 activity [23, 24] . Hypoxia also stimulates the transcription of collagenase IV gene which further contributes to matrix
The potential role of endothelin-1 (ET-1) in the pathoremodelling [24] .
genesis of pulmonary hypertension has recently been evoked [32] . ET-1 is an important vasoactive peptide produced by endothelial cells in pulmonary and systemic 3.3. Arterial and arteriolar thrombosis circulations. It is released following the stimulation by a variety of substances including: epinephrine, cytokineŝ In primary and secondary pulmonary hypertension, (such as: transforming growth factor-beta, interleukin-1), arterial thrombosis of small and medium size arteries has or following altered vascular physical factors (increased frequently been described by pathologists [25, 26] . In cases shear stress, hypoxia or cold exposure) [24] . ET-1 is of classic thromboembolic pulmonary hypertension, it is produced via the action of an endothelin-converting enthe thrombosis of major pulmonary artery which is the zyme (ECE) which converts big ET-1 to ET-1 [33] . [29] .
anatomical functional heterogeneity exists in the distribu- at Pennsylvania State University on March 6, 2014 http://cardiovascres.oxfordjournals.org/ Downloaded from tion of ET-1 receptors. It was hence noted that while ET interaction [46] . Transient expression studies showed that A receptors mediate vasoconstriction in the large elastic nitric oxide exposure suppressed hypoxia-induced VEGF arteries, in pulmonary resistance arteries of rats it is the gene transcription [47] . ET receptors which mediate vasoconstriction [34] . In a Endothelial cells cultured under low oxygen pressure B lung perfusion system, ET-1 binds to its receptor on also release a platelet-derived growth factor (PDGF) [24] . vascular smooth muscle cells (mainly ET ) and has no PDGF induces vasoconstriction and stimulates pulmonary A effect on endothelial cells, which could explain sustained artery fibroblasts migration and proliferation [21] . Endopulmonary arterial vasoconstriction [35] . Interaction of thelin, a vasoactive mediator produced by endothelial cells ET-1 with its ET receptor could therefore explain susalso induces chemotaxis and replication of the fibroblasts A tained pulmonary arterial vasoconstriction.
[48]. In humans, ET-1 was first associated with secondary pulmonary hypertension in children with congenital heart 4.3. Role of prostaglandins defects [36] . Increased levels of ET-1 in systemic and pulmonary blood in the course of pulmonary hypertension, Endothelial cells produce a vasodilator and antiagregant and evidence for its excessive production within the lungs prostaglandin, prostacyclin, while platelets produce throm-(following biopsies of patients with pulmonary hypertenboxane A , a prothrombotic prostaglandin. In patients with 2 sion compared with healthy subjects), was demonstrated primary pulmonary hypertension, the levels of prostacyclin [31, 37] . Endothelin-1 systemic concentrations were also are reduced compared with those of thromboxane A 2 found to be greater in primary versus secondary pulmonary metabolites [49] . These results however were not conhypertension [37] . In lung biopsies of patients with pulfirmed by a later study [50] . Prostacyclin modulates the monary hypertension, compared with normal lungs, Giaid vasodilator response of arteriolar muscular cells in the case showed that the pulmonary arteries' endothelium has a of acute hypoxia [51] . This response decreases in cases of strong immunoreactivity for ECE-1, suggesting that eleprolonged hypoxia [52] . Decreased prostacyclin levels are vated plasma concentrations of this peptide could result also partly responsible for the prothrombotic state noted in from an amplified conversion of big ET-1 to ET-1 [38] . pulmonary hypertension. Increased platelet activation and Bialecki et al. suggested that the hypoxia-induced changes decreased platelet survival were reported [28] and are in arterial responsiveness to ET-1 might be the cause of normalised after prostacyclin infusion [53] . However, other increased ET-1 plasmatic concentrations [39] . In hypoxic studies concerning the circulating levels of stable platelet rats, a treatment with oral ETA receptor antagonist led to a activation markers (such as: thromboxane B2, b-thrombogvasodilatation and a decreased right ventricular pressure lobulin and platelet factor 4) show conflicting results [54] . [40] . This beneficial effect was due to restoration of the nitric oxide-induced smooth muscle cells' relaxation and 4.4. Role of nitric oxide endothelium-dependent dilation in response to acetylcholine [41] . These experiments establish a link between ET-1 Nitric oxide (NO) usually contributes to maintain a low and nitric oxide roles during hypoxia and in pulmonary blood pressure in the pulmonary circulation. NO is prohypertension [24] .
duced by endothelial cells through the action of nitric oxide synthase (NOS). In hypoxic rats lungs, northern blot analysis show that smooth muscle cells, macrophages, and epithelial cells the level of eNOS mRNA increases significantly, as well [42] . Endothelial cells do not secrete VEGF under physioas the two mRNA detected for iNOS [56] . Western blot logical conditions. VEGF has however been found in analysis confirm a significant increase in eNOS and iNOS plexiform lesions of patients with primary pulmonary proteins. De novo eNOS immunostaining is revealed in hypertension. Furthermore, in monocytic cell line and small and medium-sized arteries of hypoxic rats compared isolated lung experiments, the gene encoding for VEGF is with staining nearly exclusively limited to large-sized stimulated almost instantly following hypoxia [43] . Exarteries in normoxic rats [57] . Increased NOS expression perimental serial deletions of VEGF gene promoter idendoes not necessarily correspond to an increased NO tified a 28-bp fragment which is necessary for hypoxia activity. However, in chronically hypoxic rats, NO-syninducement of VEGF. This fragment is recognised by thesis blockade with L-arginine analogue enhances pul-HIF-1, a transcription factor essential to the hypoxia monary vasoconstriction induced by acute hypoxia [56] response [44, 45] . The transcriptional activation of the and increased NOS activity was noted to coincide with the VEGF gene is subsequent to a VEGF promoter and HIF-1 beginning of the vascular remodelling process during at Pennsylvania State University on March 6, 2014
http://cardiovascres.oxfordjournals.org/ Downloaded from chronic hypoxia [58] . In hypoxic bovine endothelial cells, 5. Therapeutic applications of prostacyclin and NO Palmer et al. showed that the interaction of HIF-1 with based on their roles in pulmonary hypertension iNOS gene promoter regulated transcription of i-NOS gene [59] .
Pulmonary hypertension considered for a long time as a In humans, nNOS is found in normal vascular endodreadful and hopeless disease is now under better medical thelium [60] but its immunostaining is not increased in and surgical management [73] . Non specific therapy patients with pulmonary hypertension as compared with (diuretics and digoxin) were initially used with nondrug controls [61] . eNOS showed strong immunostaining in treatment such as oxygen supplementation. The latter almost all plexiform lesions in cases of pulmonary hyremains the main treatment when pulmonary hypertension pertension when compared with normal lung tissue [62] .
is due to chronic obstructive pulmonary disease. Present These results however contradict Giaid's et al. previous treatments ensue from the roles of vasoconstriction and findings of a reduced expression of eNOS mRNA and thrombosis in pulmonary hypertension. Initial evaluation immunoreactivity in the lungs of patients with pulmonary of a patient with pulmonary hypertension includes a hypertension [63] . Therefore, if chronic hypoxia leads to detailed medical history and clinical examination in order an up-regulation of iNOS and eNOS in hypoxic rats, the to identify possible causes of secondary pulmonary hyresults in humans are still conflicting [62, 63] . pertension. It is followed by right heart catheterization for precise pressure measurements and testing of calcium 4.5. Other prothrombotic factors antagonists or short-acting molecule such as NO, or prostacyclin analogue such as epoprostenol [74] . The As reported in isolated cases [64, 65] and in a prospecanticipated response to these substances is pulmonary tive study [66] , anti-phospholipid antibodies may be arterial vasodilatation with a subsequent reduction in implicated in the pulmonary arterial thrombotic process. In pulmonary vascular resistance. It only occurs in 25% of all a study of 38 patients, anti-phospholipid antibodies were patients tested and is considered as favourable because found in 44% of the precapillary pulmonary hypertension long term treatment with calcium antagonists is effective in cases, where in situ thromboses are frequently observed such cases. In a 5-years prospective study of 64 patients [66] . Decreased levels of thrombomodulin, an antithromwith primary pulmonary hypertension, 17 patients respondbotic factor present on the luminal part of endothelial cells, ed to calcium-channel antagonists with a 20% decrease in were found in secondary pulmonary hypertension [67, 68] .
pulmonary-artery pressure [75] . They received a long-term Decreased fibrinolytic activity with elevated plasminogen (5 years) and high dose calcium-channels antagonists activator inhibitor-1 activity was shown in primary pultreatment (mean daily dose of nifedipine: 172 mg). Five monary hypertension [69] .
years later, patients who responded to the vasodilator In sum, an imbalance due to increased thrombotic treatment had an increased survival (94%) as compared factors (endothelin-1, thromboxane A , antiphospholipid with the patients who did not (55%). The effect of lower 2 antibodies) with diminished fibrinolytic activity and antiagdoses of calcium-channel antagonists was not examined in gregant endothelial factors (prostacyclin, thrombomodulin, this study. Anticoagulation increased survival of patients nitric oxide) favours thrombosis in pulmonary hypertenwith primary pulmonary hypertension who did not respond sion.
to calcium-channel antagonists [75] and a retrospective study demonstrated an increased survival of patients with 4.6. Role of inflammation pulmonary hypertension treated with anticoagulants [26] . Anticoagulation is therefore a recommended treatment of In some patients with pulmonary hypertension, plasma pulmonary hypertension with a target INR (international pro-inflammatory cytokines such as tumour necrosis normalised ratio) between 2 and 3. When these treatments factor-a, interleukin-1b and interleukin-6, are elevated do not improve clinical and hemodynamic parameters, a [70] . Interleukin-1b which stimulates both ET-1 and prostacyclin analogue infusion or inhaled NO is used. The PDGF production may act as a link between endothelial prostacyclin analogue epoprostenol is delivered via condysfunction, increased matrix synthesis and inflammation tinuous intravenous infusion. Long-term infusion (3 [70] . Interleukin-8, whose gene expression is stimulated by months) has favourable hemodynamics effects with a hypoxia, could be another link between hypoxia and decrease of mean pulmonary artery pressure (-4,8 mmHg) inflammation [71] . A local pro-inflammatory enzyme like and pulmonary vascular resistance (-3,4 mmHg / l / min) 5-lipoxygenase, abundantly present in alveolar macro- [74] . Most patients (39 among 41 patients) received the phages, shows more intense immuno-histochemical stainfull 3 months treatment. The main complications of ing in small arteries of patients with primary pulmonary epoprostenol treatment, due to its exclusive intravenous hypertension as compared with controls [72] . The role of delivery, were catheter-related infectious or thrombotic the mediators of local and general inflammation is probaevents. The beneficial effects of epoprostenol are indepenbly underestimated in the pathogenesis of pulmonary dent from the causal disease [76, 77] or from the effects of hypertension [15] .
brief infusions used during hemodynamic explorations. children. It has been used for shorter periods than pros- hypertension has led to progress in its management with pulmonary hypertension refractory to standard treatment. 
